Vertex Pharmaceuticals Inc. financial statements, including revenue, expenses, profit, and loss

The total revenue of VX1 for the last quarter is 2.46 B EUR, and it's 1.23% lower compared to the previous quarter. The net income of Q2 24 is -3.35 B EUR.